Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Roche acquired rights to an obesity therapy by Danish biotech firm Zealand Pharma in a collaboration deal worth up to $5.3 ...

Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss drugmaker’s effort to get into a hot market dominated by Novo Nordisk A/S and ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

A big dampener to Lupin’s plans would be the potential imposition of tariff on pharma products by the Trump government.

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

CHICAGO —Jeff Lilly has been named WGN-TV director of technology effective March 17, 2025, according to Ric Harris, WGN-TV ...

The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...

We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

Roller-coaster healthcare stock Hims & Hers Health ( HIMS 5.26%), whose stock got devastated last week by worries that it ...